Human Liver Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (2D Models, 3D Bio Printing, Liver Organoids), By Application (Drug Discovery, Academics & Research), By Region, & Competition, 2020-2030F

Market Overview

Global Human Liver Model Market was valued at USD 615.95 Million in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.12% through 2030. The Global Human Liver Model Market is expanding rapidly, driven by breakthroughs in bioengineering, rising liver disease prevalence, and the growing need for more precise drug testing platforms. As metabolic disorders, viral hepatitis, and alcohol-related liver conditions continue to surge, pharmaceutical and biotechnology companies are making significant investments in advanced liver models to enhance drug discovery, toxicity screening, and regenerative medicine research.  

The increasing incidence of liver cancer, coupled with high mortality rates, underscores the urgent need for more effective and predictive research models. Additionally, the shortage of donor organs for liver transplants has accelerated the development of bioengineered liver tissues and alternative therapeutic solutions, driving further innovation in the field.

Key Market Drivers

Pharmaceutical Research Advancements

The Global Human Liver Model Market is experiencing a transformative surge in demand, driven in large part by the rapid advancements in pharmaceutical research. As the pharmaceutical industry faces increasing pressure to develop safer and more effective drugs while reducing time and costs, human liver models have emerged as indispensable tools.

Pharmaceutical companies are continually searching for more efficient and accurate ways to evaluate drug candidates. Human liver models provide a realistic and dynamic environment to test potential drugs, predict their pharmacokinetics, and assess their toxicity. This level of precision significantly reduces the risk of late-stage clinical trial failures, leading to substantial cost savings and a more streamlined drug development process.

The pharmaceutical landscape is shifting towards personalized medicine, where treatments are tailored to individual patients based on their genetic makeup and unique disease profiles. Human liver models play a pivotal role in this paradigm by allowing researchers to test drug responses on patient-derived liver tissue. Advancements in this area are driving demand for more advanced liver models, leading to innovations and market growth.

Regulatory bodies like the FDA are increasingly emphasizing the need for human-relevant data in drug development and safety assessments. Human liver models, with their ability to mimic human liver functions accurately, are becoming a preferred choice for preclinical studies. As regulatory guidelines evolve to reflect this trend, pharmaceutical companies are investing in these models to ensure compliance and streamline the drug approval process.

Recent global health crises, such as the COVID-19 pandemic, have underscored the urgency of rapid drug development. Human liver models have played a crucial role in studying the impact of viruses on the liver and screening potential treatments. These models enable scientists to expedite research during health emergencies, increasing their importance in the pharmaceutical research landscape.

Ethical concerns and a desire for more humane research practices have led to a push for reduced animal testing. Human liver models provide a viable alternative that allows researchers to obtain human-specific data without harming animals. Pharmaceutical companies are increasingly adopting these models as part of their commitment to ethical research and to meet changing regulatory requirements.

Collaboration between pharmaceutical companies, academic institutions, and technology firms is driving innovation in human liver models. Partnerships leverage collective expertise and resources to develop more advanced and scalable models. These collaborative efforts have the potential to accelerate the growth of the human liver model market.

Rising Incidence of Liver Diseases

The increasing incidence of liver diseases worldwide is one of the most significant factors driving the growth of the Global Human Liver Model Market. Liver diseases, including cirrhosis, viral hepatitis, and liver cancer, are responsible for over two million deaths annually, accounting for 4% of global mortality—equivalent to one in every 25 deaths worldwide. Notably, one in three liver-related fatalities occurs among females, highlighting a significant gender-specific impact.  As the burden of liver-related disorders continues to rise due to lifestyle changes, metabolic syndromes, and environmental factors, the demand for advanced liver models in research, drug development, and toxicity testing is expanding rapidly. Liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) are increasing at an alarming rate. Obesity is a major driver of liver-related disorders, particularly non-alcoholic fatty liver disease (NAFLD), which affects 25-30% of the global population. However, its prevalence escalates sharply to 50-90% among obese individuals, underscoring a direct correlation between excess weight and liver dysfunction. The global surge in obesity and type 2 diabetes has led to a higher prevalence of NAFLD and NASH, affecting millions of people worldwide.  Rising alcohol consumption, particularly in developed markets, has significantly increased cases of alcoholic liver disease (ALD). Hepatitis B and C infections continue to contribute to chronic liver diseases, particularly in developing regions.

The rise in liver diseases has intensified research efforts in drug discovery and development.  Despite the growing patient population, there are limited approved therapies for NAFLD and NASH, prompting pharmaceutical companies to invest heavily in R&D. Liver-related clinical trials, especially those focused on acute-on-chronic liver failure (ACLF), face high failure rates, with 28-day mortality reaching up to 33.9%. Key contributors to mortality include sepsis and multi-organ failure, making timely liver transplantation critical for improving patient survival and clinical outcomes. Many liver disease drug candidates fail in clinical trials due to poor efficacy or unexpected liver toxicity. Advanced human liver models (such as 3D organoids and bioengineered tissues) help improve drug screening accuracy, reducing failure rates. The shift toward precision medicine in liver disease treatment has increased the need for patient-specific liver models, enabling tailored drug development.

Liver toxicity remains a leading cause of drug withdrawal from the market. The increasing prevalence of liver disorders has led regulatory agencies to impose stricter guidelines on drug safety evaluations.  Companies are using advanced human-derived liver models to assess drug-induced liver injury (DILI) before clinical trials. With growing regulatory pressure and ethical concerns, human liver models serve as a superior alternative to traditional animal testing, offering more reliable and human-relevant data.

Download Free Sample Report

Key Market Challenges

Complexity of Liver Functionality

The liver is an incredibly complex organ with numerous functions, including detoxification, metabolism, and protein synthesis. Replicating all of its functions accurately in a model is challenging. Researchers are working on improving the physiological relevance of liver models, but achieving a complete emulation remains a formidable task.

Long-term Viability

Maintaining the viability and functionality of human liver models over an extended period is a challenge. Cells in these models can deteriorate over time, affecting the reliability of experimental results. Researchers are exploring strategies such as bioprinting and organ-on-a-chip technology to address this issue.

Interactions with Other Organs

While single liver models provide valuable insights, understanding how the liver interacts with other organs is crucial for comprehensive research. Developing multi-organ systems that replicate these interactions accurately is a challenge that researchers are actively addressing.

Key Market Trends

Multi-Organ-on-a-Chip Systems

The development of multi-organ-on-a-chip systems is a groundbreaking trend. These platforms enable the study of interactions between the liver and other organs, providing a more comprehensive understanding of how drugs and diseases affect the entire human body. Such models hold immense promise for advancing drug development and personalized medicine.

Advanced Tissue Engineering and 3D Bioprinting

Tissue engineering and 3D bioprinting technologies are evolving rapidly. These innovations allow for the creation of highly complex and physiologically accurate liver tissues that closely mimic the real organ. The increased sophistication of liver models enhances their relevance and reliability in drug testing.

Microfluidic and Lab-on-a-Chip Devices

Microfluidic and lab-on-a-chip devices are becoming more sophisticated, enabling precise control of experimental conditions. These platforms offer real-time monitoring and analysis of liver functions, providing valuable insights into drug responses and disease mechanisms.

Segmental Insights

Product Insights

Based on the category of Product, 2D Models segment emerges as the fastest growing segment in the Global Human Liver Model Market for several compelling reasons. They offer cost-effective and efficient solutions for studying liver-related diseases and drug testing, making them an attractive choice for both research institutions and pharmaceutical companies. Also, 2D Models have been widely adopted and validated over the years, establishing a robust foundation for continued use. Their simplicity and ease of use also contribute to their enduring popularity. As advancements in cell culture techniques and assay development continue to enhance the relevance and accuracy of 2D Models, they are likely to remain the go-to choose for liver research. In the coming years, the growing demand for liver-related studies and the practical advantages of 2D Models are expected to cement their dominant position in the market.

Download Free Sample Report

Regional Insights

In 2024, Based on region North America emerges as the largest market in the Global Huma Liver Model Market during the forecast period. In the United States, nonalcoholic fatty liver disease (NAFLD) affects 38% of the population, marking a 50% increase over the past three decades. Among individuals with type 2 diabetes, NAFLD prevalence is significantly higher, ranging from 55% to 70%, underscoring the strong link between metabolic disorders and liver disease. Increasing alcohol consumption has led to a surge in cirrhosis and liver failure cases. Despite strong vaccination programs, chronic hepatitis cases persist, fueling demand for advanced liver models.

In 2025, the American Cancer Society projects 42,240 new cases of primary liver cancer and intrahepatic bile duct cancer in the United States, with 28,220 cases in men and 14,020 in women. Additionally, these cancers are expected to cause 30,090 deaths (19,250 men and 10,840 women). Since 1980, liver cancer incidence rates have more than tripled, while mortality rates have more than doubled, reflecting a sharp and persistent rise in disease burden. As the financial burden of liver diseases rises, pharmaceutical and biotech companies are accelerating their investments in human liver models to develop more effective treatments and therapies.

Recent Developments

• In October 2024, MIMETAS has unveiled a breakthrough microvascularized in vitro liver model in a recent Biofabrication publication. This advancement marks a significant milestone in drug discovery and disease research, offering a more physiologically relevant platform for studying liver function. By overcoming key challenges in replicating liver physiology in non-clinical settings, this innovation enhances preclinical drug testing and disease modeling, driving greater accuracy and efficiency in pharmaceutical development.
• In September 2024, The FDA’s Center for Drug Evaluation and Research (CDER) accepted the first organ-on-a-chip technology submission under its Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program. This micro-physiological system (MPS) is specifically designed to predict drug-induced liver injury (DILI) in certain drug candidates, representing a major step toward improving preclinical drug safety assessments and reducing reliance on traditional testing models.
• In June 2024, Researchers at King’s College London (KCL) have developed a mini lab-grown liver model that offers a more effective and ethical alternative for drug testing. This innovative model, created by integrating liver cells with synthetic nanoscaffolds, provides a highly predictive platform for preclinical drug screening and toxicity testing. By closely mimicking human liver function, it presents a viable replacement for traditional animal models, enhancing both accuracy and efficiency in pharmaceutical development.
• In January 2024, A new 3D bioprinted liver model has been developed as an advanced tool for studying metabolic dysfunction–associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). This serious complication of metabolic dysfunction–associated steatotic liver disease (MASLD), previously referred to as nonalcoholic fatty liver disease (NAFLD), remains unrelated to alcohol consumption. The recent terminology shift aims to eliminate stigma associated with the previous naming conventions. This cutting-edge 3D model holds promise for enhancing disease research and accelerating the development of effective treatments.

Key Market Players

• Organovo Holdings Inc
• BioIVT LLC
• InSphero AG
• Emulate Inc
• Mimetas BV
• CN Bio
• Cyfuse Biomedical KK
• Hurel Corp

Report Scope:

In this report, the Global Human Liver Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Human Liver Model Market, By Product:

o   2D Models

o   3D Bio Printing

o   Liver Organoids

• Human Liver Model Market, By Application:

o   Drug Discovery

o   Academics & Research

• Human Liver Model Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  Germany

§  United Kingdom

§  France

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  Japan

§  India

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Liver Model Market.

Available Customizations:

Global Human Liver Model market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).